论文部分内容阅读
目的 :探讨多药耐药糖蛋白 (P- gp)的发生规律。方法 :以 MDR1 基因、P- gp和 blc- 2蛋白表达的测定为主要实验室指标 ,根据 93例初治急性非淋巴细胞白血病患者的临床资料的结果 ,分析 P- gp发生规律及其与临床疗效之间的关系。结果 :年龄 >6 0岁、骨髓涂片中两系以上的病态造血以及巨核细胞不减少与初诊时 P- gp的表达水平呈正相关。结论 :上述临床特征易诱发继发性 P- gp过度表达。MEA方案以及高剂量化疗诱发继发性 P- gp表达的作用弱于 DA和 HA方案及非高剂量化疗。
Objective: To investigate the occurrence of multidrug resistance glycoprotein (P-gp). Methods: The MDR1 gene, P-gp and blc-2 proteins were measured as the main laboratory indicators. Based on the clinical data of 93 patients with initially treated acute non-lymphocytic leukemia, the incidence of P-gp and its clinical significance were analyzed. The relationship between efficacy. Results: There was a positive correlation between P-gp expression at the first visit and age of >60 years, pathological hematopoiesis in two or more lines of bone marrow smear, and no decrease in megakaryocytes. Conclusion: The above clinical features are likely to induce secondary overexpression of P-gp. The effect of MEA regimen and high-dose chemotherapy on the induction of secondary P-gp expression was weaker than DA and HA regimens and non-high-dose chemotherapy.